Table 2 Cyclin D1, CDK4 and p16 expression in breast cancer in relation to clinicopathological variables

Tumour

   T1

21 (52.5)

41 (73.2)

14 (56.0)

39 (65.0)

27 (64.3)

32 (62.7)

   T2

13 (32.5)

12 (21.4)

10 (40.0)

14 (23.4)

10 (23.8)

15 (29.4)

   T3

3 (7.5)

3 (5.4)

1 (4.0)

5 (8.3)

2 (4.8)

4 (7.8)

   T4

3 (7.5)

0 (0.0)

0 (0.0)

2 (3.3)

3 (7.1)

0 (0.0)

0.066

0.431

0.273

Nodus

   Negative

20 (51.3)

34 (61.8)

15 (65.2)

34 (56.7)

26 (61.9)

29 (59.2)

   Positive

19 (48.7)

21 (38.2)

8 (34.8)

26 (43.3)

16 (38.1)

20 (40.8)

0.309

0.478

0.791

Grade

   I

9 (22.5)

20 (35.7)

11 (44.0)

14 (23.3)

11 (26.2)

17 (33.3)

   II

10 (25.0)

23 (41.1)

6 (24.0)

22 (36.7)

14 (33.3)

16 (31.4)

   III

21 (52.5)

13 (23.2)

8 (32.0)

24 (40.0)

17 (42.5)

18(35.3)

0.013*

0.156

0.747

Estrogen receptor (ER)

   Negative

18 (45.0)

3 (5.4)

6 (24.0)

14 (23.3)

10 (23.8)

12 (23.5)

   Positive

22 (55.0)

53 (96.6)

19 (76.0)

46 (76.7)

32 (76.2)

39 (76,5)

0.000***

0.947

0.975

Progesterone receptor (PR)

   Negative

18 (45.0)

13 (23.3)

8 (32.0)

22 (36.7)

15 (35.7)

18 (35.3)

   Positive

22 (55.00)

43 (76.8)

17 (68.0)

38 (63.3)

27 (64.3)

33 (64.7)

0.024*

0.682

0.966

HER2

   Negative

30 (75.0)

48 (85.7)

21 (84.0)

48 (80.0)

28 (66.7)

47 (92.2)

   Positive

10 (25.0)

8 (14.3)

4 (16.0)

12 (20.0)

14 (33.3)

4 (7.8)

0.185

0.769

0.002**

Ki67

   Negative

8 (20.0)

12 (21.4)

6 (24.0)

9 (15.0)

8 (19.0)

10 (19.6)

   +

10 (25.0)

24 (42.9)

11 (44.0)

21 (35.0)

15 (35.7)

18 (35.3)

   ++

7 (17.5)

13 (23.2)

2 (8.0)

16 (26.7)

10 (23.8)

9 (17.6)

   +++

15 (37.5)

7 (12.5)

6 (24.0)

14 (23.3)

9 (21.4)

14 (27.5)

0.031*

0.251

0.856